Results 201 to 210 of about 1,868 (233)

Exploration and evaluation of adverse event signals of droxidopa based on the FAERS database.

Expert Opinion on Drug Safety
BACKGROUND This study aims to utilize the FDA's Adverse Event Reporting System (FAERS) for data analysis to explore the potential adverse events associated with Droxidopa in real-world settings, thereby providing reference information for clinical ...
Xinnan Chen, Haohao Zhu, Ying Jiang, Man Tian   +3 more
semanticscholar   +1 more source

L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension

Clinical Autonomic Research, 2008
Neurogenic orthostatic hypotension is a cardinal feature of generalised autonomic failure and commonly is the presenting sign in patients with primary autonomic failure. Orthostatic hypotension can result in considerable morbidity and even mortality and is a major management problem in disorders such as pure autonomic failure, multiple system atrophy ...
Christopher J. Mathias, Christopher J. Mathias   +1 more
openaire   +3 more sources

A quality by design (QbD) strategy for developing and validating Droxidopa in API and formulation using an RP-HPLC procedure ensuring regulatory compliance

Analytical Chemistry Letters
Background: Droxidopa, a prodrug for neurogenic orthostatic hypotension, requires precise quality analysis. RP-HPLC is valued for its sensitivity and reliability in pharmaceutical quality control, but traditional methods are time-consuming and lack ...
Sandhya Madhuri Maddala, Ravi Parimi, Pravallika K Elvina   +2 more
semanticscholar   +1 more source

DBH deficiency in an elderly patient: efficacy and safety of chronic droxidopa

Clinical Autonomic Research, 2010
We describe the effects of chronic droxidopa in a patient with Dopamine beta-hydroxylase deficiency diagnosed at the age of 73. Investigations were performed to assess sympathetic activity (MIBG scintigraphy, catecholamines) and cardiovascular droxidopa safety.
P. Massabuau, M. Galinier, R. Cagnac, Fabien Despas, M. Berry, Jean-Michel Senard, Jean-Michel Senard, Jean-Michel Senard, A. Pathak, A. Pathak, A. Pathak, E. Liozon   +11 more
openaire   +3 more sources

Droxidopa: A Review of Its Use in Symptomatic Neurogenic Orthostatic Hypotension

Drugs, 2015
The norepinephrine prodrug droxidopa (NORTHERA™) is approved in the US for the treatment of orthostatic dizziness, lightheadedness, or the 'feeling that you are about to black out' in adults with symptomatic neurogenic orthostatic hypotension associated with primary autonomic failure (e.g.
exaly   +4 more sources

Efficient Detection of Droxidopa in the Presence of Carbidopa Using a Modified Screen-Printed Graphite Electrode

Topics in catalysis, 2023
Sayed Ali Ahmadi, Somayeh Tajik
semanticscholar   +1 more source

Amantadine/droxidopa

Reactions weekly, 2023

semanticscholar   +1 more source

[Study on the metabolism of droxidopa in humans].

Rinsho shinkeigaku = Clinical neurology, 1995
Supplement of the deficient neurotransmitters is one of the most effective therapies for neurodegenerative disorders. For the treatment of Parkinson's disease, L-DOPA therapy has been applied to replace dopamine, and droxidopa (L-threo-3,4-dihydroxyphenylserine) therapy to supply noradrenaline (NA).
W, Maruyama, M, Naoi, H, Narabayashi
openaire   +1 more source

Droxidopa for the Treatment of Parkinson’s Disease

2020
Mizuki Ito, Hirohisa Watanabe
openaire   +1 more source

Droxidopa reduces postural sway in Parkinson disease patients with orthostatic hypotension.

Parkinsonism & Related Disorders, 2022
L. Marsili, K. Duque, Andrea Sturchio, G. Sobrero, I. Premoli, A. Dwivedi, A. Espay, A. Merola   +7 more
semanticscholar   +1 more source